

Guidelines on Renal Cell Carcinoma

B. Ljungberg, D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger,
P.F.A. Mulders, J-J. Patard, I.C. Sinescu

TABLE OF CONTENTS

PAGE

1	INTRODUCTION	4
2	BACKGROUND: EPIDEMIOLOGY AND AETIOLOGY	4
2.1	Conclusion	4
2.2	Recommendation	5
2.3	References	5
3	DIAGNOSIS AND STAGING	5
3.1	Symptoms	5
3.1.1	Physical examination	6
3.1.2	Laboratory findings	6
3.2	Radiological investigations	6
3.3	Conclusion	6
3.4	Recommendation	6
3.5	References	6
4	CLASSIFICATION AND PROGNOSTIC FACTORS	8
4.1	Classification	8
4.2	Prognostic factors	8
4.2.1	Anatomical factors	9
4.2.2	Histological factors	9
4.2.3	Clinical factors	10
4.2.4	Molecular factors	10
4.2.5	Prognostic systems and nomograms	10
4.3	Conclusion	10
4.4	Recommendations for classification and prognosis	10
4.5	References	10
5	TREATMENT OF LOCALIZED DISEASE	13
5.1	Surgery	13
5.1.1	Embolization	13
5.1.1.1	Conclusion	13
5.1.1.2	Recommendation	13
5.1.2	Nephron-sparing surgery	13
5.1.2.1	Conclusion	13
5.1.2.2	Recommendation	14
5.1.3	Laparoscopic nephrectomy	14
5.1.3.1	Conclusion	14
5.1.3.2	Recommendation	14
5.1.4	Partial laparoscopic nephrectomy	14
5.1.4.1	Conclusion	14
5.1.4.2	Recommendation	14
5.2	Alternative treatment	14
5.2.1	Conclusion	15
5.2.2	Recommendation	15
5.3	Adjuvant therapy	15
5.3.1	Conclusion	15
5.3.2	Recommendation	15
5.4	Surgical treatment of metastatic RCC (tumour nephrectomy)	15
5.4.1	Conclusion	15
5.4.2	Recommendation	15
5.5	Resection of metastases	15
5.5.1	Conclusion	15
5.5.2	Recommendation	16
5.6	Radiotherapy for metastases in RCC	16
5.6.1	Conclusion	16
5.6.2	Recommendation	16
5.7	References	16

6	SYSTEMIC THERAPY FOR METASTATIC RCC	21
6.1	Chemotherapy	21
6.1.1	Conclusion	21
6.1.2	Recommendation	21
6.2	Immunotherapy	21
6.2.1	Interferon-alpha	21
6.2.1.1	Conclusion	21
6.2.2	Interleukin-2	21
6.2.2.1	Conclusion	21
6.2.3	Combinations of cytokines	21
6.2.3.1	Conclusion	21
6.2.4	Recommendations	21
6.3	Angiogenesis inhibitor drugs	22
6.3.1	Sorafenib	22
6.3.2	Sunitinib	22
6.3.3	New drugs	22
6.3.4	Conclusion	22
6.3.5	Recommendations	22
6.4	References	23
7	SURVEILLANCE FOLLOWING RADICAL SURGERY FOR RCC	25
7.1	Introduction	25
7.2	Which investigations for which patient, and when?	25
7.3	Imaging modalities	25
7.4	Conclusion	26
7.5	Recommendation	26
7.6	References	27
8	ABBREVIATIONS USED IN THE TEXT	28

1. INTRODUCTION

The EAU Guideline Group for renal cell carcinoma (RCC) have prepared this guideline to help urologists assess the evidence-based management of RCC and to incorporate the guideline recommendations into their clinical practice. Publications concerning RCC are mostly based on retrospective analysis, including some larger multicentre studies and well-designed controlled studies. Only a few randomized studies are available, so that it is difficult to obtain qualified evidence-based data.

The recommendations provided in the current guideline are based on a systemic literature search using Medline, the Cochrane Central Register of Controlled Trials, and reference lists in publications and review articles. The level of evidence available for the information given in this guideline is listed below (Table 1).

There is clearly a need for continuous re-evaluation of the information inherent in the current guideline at regular intervals by the RCC Guideline Group. It has to be emphasized that the current guideline contains information for the treatment of an individual patient according to a standardized general approach. The information should be considered as providing recommendations without legal implications.

Table 1: Levels of evidence and grade of guideline recommendations as used by EAU (1)

Level	Type of evidence
1a	Evidence obtained from meta-analysis of randomized trials
1b	Evidence obtained from at least one randomized trial
2a	Evidence obtained from one well-designed controlled study without randomization
2b	Evidence obtained from at least one other type of well-designed quasi-experimental study
3	Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports
4	Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities

Grade	Nature of recommendations
A	Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomized trial
B	Based on well-conducted clinical studies, but without randomized clinical trials
C	Made despite the absence of directly applicable clinical studies of good quality

2. BACKGROUND: EPIDEMIOLOGY AND AETIOLOGY

Renal cell carcinoma represents 2-3% of all cancers (2), with the highest incidence occurring in the more developed countries. The worldwide and European annual increase in incidence is approximately 2%, though in Denmark and Sweden a continuing decrease has been observed during the last two decades (3). In 1998, about 30,000 patients were diagnosed with kidney cancer within the European Union and approximately 15,000 died of the disease (4).

Renal cell carcinoma is the most frequently occurring solid lesion within the kidney and comprises different RCC types with specific histopathological and genetic characteristics (5). There is a 1.5:1 predominance of men over women, with peak incidence occurring between 60 and 70 years of age. Aetiological factors include lifestyle factors, such as smoking, obesity and antihypertensive therapy (3,6,7). The most effective prophylaxis is to avoid cigarette smoking.

Due to the increased detection of tumours by the use of imaging techniques such as ultrasound and computerized tomography (CT), an increasing number of incidentally diagnosed RCCs are found. These tumours are more often smaller and of lower stage (8-10). Despite the increased incidental detection rate, the mortality from RCC has remained unaffected and parallel to the incidence.

2.1 Conclusion

A number of aetiological factors have been identified including smoking, obesity and antihypertensive drugs. Cigarette smoking is a definite risk factor for RCC (level of evidence: 2a). The roles of obesity and prolonged intake of antihypertensive medication as risk factors for RCC remain to be definitively clarified (level of evidence: 2a).

2.2 Recommendation

The most important primary prevention for RCC is to eliminate cigarette smoking and to avoid obesity (grade B recommendation).

2.3 REFERENCES

1. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1992, pp. 115-127.
2. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001), Lyon, 2001.
3. Lindblad P. Epidemiology of renal cell carcinoma. *Scand J Surg* 2004;93(2):88-96.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15285559&query_hl=3&itool=pubmed_docsum
4. EUCAN.
<http://www-dep.iarc.fr/eucan/eucan.htm>
5. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. *J Pathol* 1997;183(2):131-133.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9390023&query_hl=3&itool=pubmed_DocSum
6. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. *Br J Cancer* 2001;85(7):984-990.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11592770&query_hl=7&itool=pubmed_docsum
7. Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, Klipstein-Grobusch K, Linseisen J, Becker N, Trichopoulou A, Benetou V, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Monninkhof E, Peeters PH, Bueno-de-Mesquita HB, Buchner FL, Ljungberg B, Hallmans G, Berglund G, Gonzalez CA, Dorransoro M, Gurrea AB, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Kaaks R, Norat T, Slimani N, Riboli E. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2006;118(3):728-738.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16094628&query_hl=9&itool=pubmed_docsum
8. Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. *BJU Int* 2002;90(4):358-363.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12175389&query_hl=11&itool=pubmed_docsum
9. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. *J Urol* 2004;172(3):863-866.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15310984&query_hl=5&itool=pubmed_docsum
10. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. *J Urol* 2001;163(2):426-430.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10647646&query_hl=14&itool=pubmed_docsum

3. DIAGNOSIS AND STAGING

3.1 Symptoms

Many renal masses remain asymptomatic and non-palpable until late in the natural course of the disease (1) (level of evidence: 4). Today, more than 50% of RCCs are detected incidentally using non-invasive imaging for the evaluation of a variety of non-specific symptom complexes (1) (level of evidence: 4). The classic triad of flank pain, gross haematuria and palpable abdominal mass is now rarely found (6-10%) (2,3) (level of evidence: 3). Paraneoplastic syndromes are found in around 30% of patients with symptomatic RCC. The most common of these are: hypertension, cachexia, weight loss, pyrexia, neuromyopathy, amyloidosis, elevated erythrocyte sedimentation rate, anaemia, abnormal liver function, hypercalcaemia, polycythaemia, etc. (1) (level of evidence: 4).

A minority of patients present with symptoms directly caused by metastatic disease, such as bone

pain or persistent cough (1) (level of evidence: 4). Still, 25-30% of patients are diagnosed due to symptoms associated with metastatic disease.

3.1.1 Physical examination

Physical examination has a limited role in diagnosing RCC, but it may be valuable in some cases such as palpable abdominal mass, palpable cervical lymphadenopathy, non-reducing varicocele or bilateral lower extremity oedema, which suggests venous involvement. These findings should initiate radiological examinations.

3.1.2 Laboratory findings

The most commonly assessed laboratory parameters are haemoglobin, erythrocyte sedimentation rate, alkaline phosphatase and serum calcium (1,4) (level of evidence: 4).

3.2 Radiological investigations

The majority of renal tumours are diagnosed by abdominal ultrasound (US) and CT performed for various reasons (level of evidence: 4). Detection of a solid renal mass with US should be further investigated with a high-quality CT scan using contrast medium. It serves to verify the diagnosis of RCC and provides information on the function and morphology of the contralateral kidney (5) (level of evidence: 3). Abdominal CT assesses primary tumour extension with extrarenal spread and provides information on venous involvement, enlargement of locoregional lymph nodes, and condition of adrenal glands and the liver (level of evidence: 3). Chest CT is the most accurate investigation for chest staging (6-13) (level of evidence: 3), but at least routine chest radiography, as a less accurate alternative, must be done for metastatic evaluation (level of evidence: 3).

Magnetic resonance imaging (MRI) can be reserved primarily for patients with locally advanced malignancy, possible venous involvement, renal insufficiency or allergy to intravenous contrast (14-18) (level of evidence: 3). Magnetic resonance imaging is also an option for the evaluation of inferior vena cava tumour thrombus extension and the evaluation of unclassified renal masses (level of evidence: 3). Evaluation of the tumour thrombus can also be performed with Doppler US in such cases (19) (level of evidence: 3).

There is consensus that most bone and brain metastases are symptomatic at the time of diagnosis and that routine bone scan or brain CT are not generally indicated (20,21). If indicated by clinical or laboratory signs and symptoms, other diagnostic procedures may be applied, such as bone scan, brain CT or MRI (level of evidence: 3). Renal arteriography, inferior venacavography or fine-needle biopsy (22-24) have only a limited role in the clinical work-up of patients with RCC, but may be considered in selected cases (level of evidence: 3).

3.3 Conclusion

In Europe, a large number of patients with RCC are still diagnosed due to clinical symptoms, such as palpable mass and haematuria, paraneoplastic and metastatic symptoms (level of evidence: 3). The number of incidentally detected RCCs is significantly increasing. Accurate staging of RCC with abdominal and chest CT or MRI is obligatory (level of evidence: 3). Chest CT is the most sensitive approach for chest staging. There is no role for routine bone scan or CT of the brain in the standard clinical work-up of asymptomatic patients. There is only a limited indication for fine-needle biopsy (level of evidence: 3).

3.4 Recommendation

In a patient with one or more of these laboratory or physical findings, the possible presence of RCC should be suspected. A plain chest X-ray can be sufficient for assessment of the lung in low-risk patients but chest CT is most sensitive. Abdominal CT and MRI are recommended for the work-up of patients with RCC and are the most appropriate imaging modalities for TNM classification prior to surgery. In high-risk patients for bone metastases (raised alkaline phosphatase or bone pain), further evaluation utilizing an imaging approach should be done (grade A recommendation).

3.5 REFERENCES

1. Novick AC, Campbell SC. Renal tumours. In: Walsh PC, Retik, AB, Vaughan ED, Wein AJ, eds. *Campbell's Urology*. Philadelphia: WB Saunders, 2002, pp. 2672-2731.
2. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. *Urol Oncol* 2002;7(4):135-140.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12474528&query_hl=17&itool=pubmed_docsum

3. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. *Eur Urol* 2003;44(2):226-232. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12875943&query_hl=19&itool=pubmed_docsum
4. Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serologic syndromes of renal adenocarcinoma. *Semin Urol* 1989;7(3):158-171. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2690260&query_hl=21&itool=pubmed_docsum
5. Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. *Urol Clin North Am* 1997;24(3):507-522. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9275976&query_hl=23&itool=pubmed_docsum
6. Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. *World J Urol* 2004;22(5):307-315. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15290202&query_hl=25&itool=pubmed_docsum
7. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. *Radiographics* 2001;21:S237-S254. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11598260&query_hl=27&itool=pubmed_docsum
8. Miles KA, London NJ, Lavelle JM, Messios N, Smart JG. CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques. *Eur J Radiol* 1991;13(1):37-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1889427&query_hl=29&itool=pubmed_docsum
9. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. *J Urol* 1993;150(4):1112-1114. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8371366&query_hl=31&itool=pubmed_docsum
10. Doda SS, Mathur RK, Buxi TS. Role of computed tomography in staging of renal cell carcinoma. *Comput Radiol* 1986;10(4):183-188. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3791984&query_hl=33&itool=pubmed_docsum
11. Fritzsche PJ, Millar C. Multimodality approach to staging renal cell carcinoma. *Urol Radiol* 1992;14(1):3-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1615571&query_hl=36&itool=pubmed_docsum
12. McClennan BL, Deyoe LA. The imaging evaluation of renal cell carcinoma: diagnosis and staging. *Radiol Clin North Am* 1994;32(1):55-69. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8284361&query_hl=38&itool=pubmed_docsum
13. Tammela TL, Leinonen AS, Kontturi MJ. Comparison of excretory urography, angiography, ultrasound and computed tomography for T category staging of renal cell carcinoma. *Scand J Urol Nephrol* 1991;25(4):283-286. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1780704&query_hl=40&itool=pubmed_docsum
14. Hricak H, Demas BE, Williams RD, McNamara MT, Hedgcock MW, Amparo EG, Tanagho EA. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. *Radiology* 1985;154(3):709-715. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3969475&query_hl=42&itool=pubmed_docsum
15. Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. *Crit Rev Diagn Imaging* 1991;32(2):69-118. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1863349&query_hl=44&itool=pubmed_docsum
16. Krestin GP, Gross-Fengels W, Marincek B. [The importance of magnetic resonance tomography in the diagnosis and staging of renal cell carcinoma.] *Radiologe* 1992;32(3):121-126. [German] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1565792&query_hl=46&itool=pubmed_docsum

17. Nishimura K, Hida S, Okada K, Yoshida O, Nishimura K. Staging and differential diagnosis of renal cell carcinoma: a comparison of magnetic resonance imaging (MRI) and computed tomography (CT). *Hinyokika Kyo* 1988;34(8):1323-1331.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3195400&query_hl=49&itool=pubmed_docsum
18. Kabala JE, Gillatt DA, Persad RA, Penry JB, Gingell JC, Chadwick D. Magnetic resonance imaging in the staging of renal cell carcinoma. *Br J Radiol* 1991;64(764):683-689.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1884119&query_hl=51&itool=pubmed_docsum
19. Gupta NP, Ansari MS, Khaitan A, Sivaramakrishna MS, Hemal AK, Dogra PN, Seth A. Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. *Urol Int* 2004;72(2):129-134.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14963353&query_hl=53&itool=pubmed_docsum
20. Hendriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. *Scand J Urol Nephrol* 1992;26(4):363-366.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1292074&query_hl=5&itool=pubmed_docsum
21. Marshall ME, Pearson T, Simpson W, Butler K, McRoberts W. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. *Urology* 1990;36(4):300-302.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2219605&query_hl=7&itool=pubmed_docsum
22. Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. *Urol* 1996;48(5):692-695.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8911510&query_hl=55&itool=pubmed_docsum
23. Brierly RD, Thomas PJ, Harrison NW, Fletcher MS, Nawrocki JD, Ashton-Key M. Evaluation of fine-needle aspiration cytology for renal masses. *BJU Int* 2000;85(1):14-18.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10619937&query_hl=57&itool=pubmed_docsum
24. Dechet CB, Zincke H, Sebo TJ, King BF, LeRoy AJ, Farrow GM, Blute ML. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. *J Urol* 2003;169(1):71-74.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12478106&query_hl=59&itool=pubmed_docsum

4. CLASSIFICATION AND PROGNOSTIC FACTORS

4.1 Classification

The 2002 TNM stage classification system is generally recommended for clinical and scientific use (1). It is unclear whether the current TNM classification is optimal for the prediction of survival in patients with RCC and might be a subject for re-classification. The pT1 substratification, introduced in 2002 (1), has been validated by a number of studies (2-4) (level of evidence: 3).

However, refinements remain to be performed for pT3 tumours. Firstly, for renal sinus fat invasion only, it has not been established whether this carries the same prognostic information as does perinephric fat invasion (5,6). Secondly, many studies have suggested that adrenal invasion represents a very poor prognostic group.

It has been suggested that these RCCs should be classified as T4 tumours (7,8). Furthermore, it is still not clear whether the stratification of RCCs with venous invasion in T3b and T3c is accurate. Additional studies are required to investigate the independent prognostic value of vena caval invasion compared with renal vein invasion (9). More recently, the accuracy of the N1-N2 subclassification has been questioned (10). For adequate M-staging of patients with RCC, an accurate pre-operative imaging procedure, which is currently chest and abdominal CT, should be performed (11,12).

4.2 Prognostic factors

Factors influencing prognosis can be classified into: anatomical, histological, clinical and molecular (13).

4.2.1 Anatomical factors

Anatomical factors include tumour size, venous invasion, renal capsule invasion, adrenal involvement, and lymph node and distant metastasis. These factors are commonly gathered together in the universally used 2002 TNM staging classification system.

Table 2: The 2002 TNM staging classification system

T - Primary tumour	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
T1	Tumour ≤ 7 cm in greatest dimension, limited to the kidney
T1a	Tumour ≤ 4 cm in greatest dimension, limited to the kidney
T1b	Tumour > 4 cm but ≤ 7 cm in greatest dimension, but not more than 7 cm
T2	Tumour > 7 cm in greatest dimension, limited to the kidney
T3	Tumour extends into major veins or directly invades adrenal gland or perinephric tissues but not beyond Gerota's fascia
T3a	Tumour directly invades adrenal gland or perinephric tissues ¹ but not beyond Gerota's fascia
T3b	Tumour grossly extends into renal vein(s) ² or its segmental branches, or the vena cava below the diaphragm
T3c	Tumour grossly extends into vena cava or its wall above diaphragm
T4	Tumour directly invades beyond Gerota's fascia
N - Regional lymph nodes	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single regional lymph node
N2	Metastasis in more than 1 regional lymph node

pN0 lymphadenectomy specimen ordinarily includes 8 or more lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not met, classify as pN0

M - Distant metastasis	
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

TNM stage grouping			
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
	T1, T2, T3	N1	M0
Stage IV	T4	N0,N1	M0
	Any T	N2	M0
	Any T	Any N	M1

¹Includes renal sinus (prepelvic fat).

²Includes segmental (muscle-containing branches).

A help desk for specific questions about TNM classification is available at <http://www.uicc.org/tnm>

4.2.2 Histological factors

Histological factors include Fuhrman grade, histological subtype, presence of sarcomatoid features, microvascular invasion, tumour necrosis and collecting system invasion. Fuhrman nuclear grade is the most widely accepted histological grading system in RCC (14). Although it is subject to intra- and inter-observer discrepancies, it remains an independent prognostic factor (15) (level of evidence: 3).

According to the WHO classification (16), three major histological subtypes of RCC exist: conventional (clear cell) (80-90%), papillary (10-15%) and chromophobe (4-5%) (level of evidence: 4). Many studies have shown a trend towards a better prognosis for patients with chromophobe, papillary and conventional (clear cell) RCCs, respectively (17,18). However, the prognostic information of the RCC subtype is lost when stratified to tumour stage (18).

Among papillary RCCs, two subgroups with different outcomes have been identified (19). Type I are low-grade tumours with a chromophilic cytoplasm and a favourable prognosis. Type II are mostly high-grade

tumours with an eosinophilic cytoplasm and a great propensity for developing metastases (level of evidence: 3). The RCC type subclassification has been confirmed at the molecular level by cytogenetic and genetic analyses (20-22).

4.2.3 Clinical factors

Clinical factors include patient performance status, localized symptoms, cachexia, anaemia, platelet count (23-27) (level of evidence: 3).

4.2.4 Molecular factors

There are numerous molecular markers being investigated including: carbonic anhydrase IX (CaIX), vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF), Ki67 (proliferation), p53, PTEN (cell cycle), E-cadherin, and CD44 (cell adhesion) (21,22) (level of evidence: 3). As yet, these markers are not in widespread use. Recently, gene expression profiling has identified 259 genes, which predict survival independent of clinical prognostic factors in conventional RCCs, indicating that genetic information will improve prognostication (28).

4.2.5 Prognostic systems and nomograms

Prognostic systems and nomograms that combine independent prognostic factors have been recently developed. It has been suggested that these systems are more accurate than TNM stage or Fuhrman grade alone for predicting survival (29-32) (level of evidence: 3).

4.3 Conclusion

In patients with RCC, TNM stage, nuclear grade according to Fuhrman and RCC subtype (WHO 2004) should be performed because they contribute important prognostic information (level of evidence: 2). There are currently no prognostic integrated systems or molecular markers recommended for routine clinical use. Prognostic systems or nomograms can be useful for the stratified inclusion of patients into clinical trials (level of evidence: 2)

4.4 Recommendations for classification and prognosis

The current TNM classification system is recommended since it has consequences for prognosis and therapy. Fuhrman grading system and classification of RCC subtype should be used. The use of integrated prognostic systems or nomograms is not routinely recommended, although these systems provide a rationale for a prognostic prediction useful for including patients in clinical trials. No molecular prognostic marker is currently recommended for utilization in the clinical routine (grade B recommendation).

4.5 REFERENCES

1. Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th edn. New York: Wiley-Liss, 2002, pp. 193-195.
2. Frank I, Blute ML, Leibovich BC, Chevillet JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. *J Urol* 2005;173(6):1889-1892.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15879769&query_hl=62&itool=pubmed_docsum
3. Salama ME, Guru K, Stricker H, Peterson E, Peabody J, Menon M, Amin MB, De Peralta-Venturina M. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. *J Urol* 2005;173(5):1492-1495.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15821466&query_hl=64&itool=pubmed_docsum
4. Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, Cindolo N, Novara G, Zigeuner RE, Bratti E, Tostain J, Altieri V, Abbou CC, Artibani W, Patard JJ. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. *Cancer* 2005;104(5):968-974.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16007683&query_hl=66&itool=pubmed_docsum
5. Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. *Am J Surg Pathol* 2004;28(12):1594-1600.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15577678&query_hl=68&itool=pubmed_docsum

6. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? *J Urol* 2005;174(4 Pt 1):1218-1221.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16145373&query_hl=70&itool=pubmed_docsum
7. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukoyama H, Figlin RA, Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. *J Urol* 2003;169(3):899-903; discussion 903-904.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12576809&query_hl=40&itool=pubmed_docsum
8. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? *J Urol* 2005;173(3):918-921.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15711327&query_hl=74&itool=pubmed_docsum
9. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. *Cancer* 2005;104(1):53-60.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15895375&query_hl=76&itool=pubmed_docsum
10. Terrone C, Cracco F, Porpiglia F, Bollito E, Scoffone C, Poggio M, Berutti A, Ragni F, Cossu M, Scarpa RM, Rosetti SR. Reassessing the current TNM lymph node staging for renal cell carcinoma. *Eur Urol* 2006;49(2):324-331.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16386352&query_hl=79&itool=pubmed_docsum
11. Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. *World J Urol* 2004;22(5):307-315.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15290202&query_hl=81&itool=pubmed_docsum
12. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. *Radiographics* 2001;21:S237-S254.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11598260&query_hl=82&itool=pubmed_docsum
13. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *J Urol* 2005;173(6):1853-1862.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15879764&query_hl=83&itool=pubmed_docsum
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982;6(7):655-663.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7180965&query_hl=85&itool=pubmed_docsum
15. Lang H, Lindner V, de Fromont M, Molinie V, Letourneux H, Meyer N, Martin M, Jacqmin D. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. *Cancer* 2005;103(3):625-629.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15611969&query_hl=87&itool=pubmed_docsum
16. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyons: IARC Press, 2004, p. 7.
17. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histological subtypes of renal cell carcinoma. *Am J Surg Pathol* 2003;27(5):612-624.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12717246&query_hl=90&itool=pubmed_docsum
18. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De LaTaille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histological subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol* 2005;23(12):2763-2771.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15837991&query_hl=92&itool=pubmed_docsum

19. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. *Hum Pathol* 2001;32(6):590-595.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11431713&query_hl=94&itool=pubmed_docsum
20. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. *Clin Cancer Res* 2004;10(8 Pt 2):6282S-6289S.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15448018&query_hl=96&itool=pubmed_docsum
21. Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, Kagawa S, Hoekstra P, Curry J, Yang XJ, Teh BT. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. *Cancer Res* 2004;64(12):4117-4121.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15205321&query_hl=98&itool=pubmed_docsum
22. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. *Cancer Res* 2005;65(13):5628-5637.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15994935&query_hl=106&itool=pubmed_docsum
23. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. *J Urol* 2003;170(5):1742-1746.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14532767&query_hl=107&itool=pubmed_docsum
24. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. *J Urol* 2004;171(5):1810-1813.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15076282&query_hl=109&itool=pubmed_docsum
25. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani W, Abbou CC, Guille F, Chopin DK, Lobel B. Multi-institutional validation of a symptom based classification for renal cell carcinoma. *J Urol* 2004;172(3):858-862.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15310983&query_hl=111&itool=pubmed_docsum
26. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ. Prognostic value of thrombocytosis in renal cell carcinoma. *J Urol* 2006;175(3 Pt 1):859-863.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16469566&query_hl=114&itool=pubmed_docsum
27. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. *Eur Urol* 2003;44(2):226-232.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12875943&query_hl=116&itool=pubmed_docsum
28. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. *PLoS Med* 2006;3(1):e13. [Epub 2005 Dec 6.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16318415&query_hl=118&itool=pubmed_docsum
29. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001;166(1):63-67.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11435824&query_hl=120&itool=pubmed_docsum
30. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol* 2001;19(6):1649-1657.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11250993&query_hl=122&itool=pubmed_docsum
31. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol* 2002;168(6):2395-2400.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12441925&query_hl=124&itool=pubmed_docsum

32. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer* 2003;97(7):1663-1671.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12655523&query_hl=126&itool=pubmed_docsum

5. TREATMENT OF LOCALIZED DISEASE

5.1 Surgery

Radical nephrectomy that includes the removal of the tumour-bearing kidney remains the gold standard curative therapy for patients with localized RCC and offers a reasonable chance of curing the disease (1).

There is no evidence to favour a specific surgical approach. Except in the case of a large upper pole tumour, which is associated with a risk of direct invasion of the adrenal gland, or a tumour of > 7 cm maximum diameter, which is associated with a higher risk of intra-adrenal metastatic spread, there is evidence that a routine adrenalectomy is unnecessary during the surgical treatment of RCC, provided the pre-operative imaging procedures for tumour staging (CT, MRI) reveal negative findings.

5.1.1 Embolization

Indications for tumour embolization include patients with gross haematuria who are not fit for surgical intervention and prior to surgical resection of large paravertebral metastases. There is no benefit in performing tumour embolization before routine radical nephrectomy (level of evidence: 3) (2-8).

5.1.1.1 Conclusion

Radical nephrectomy according to Robson is no longer the gold standard treatment for smaller renal tumours (level of evidence: 2b). Adrenalectomy is not recommended provided the adrenal is normal on pre-operative CT scan (level of evidence: 3). About half of adrenal metastases develop from larger upper pole tumours (level of evidence: 3). Lymphadenectomy should be restricted to the perihilar tissue for staging purposes since extended lymphadenectomy does not improve survival (level of evidence: 2b). Renal cell carcinomas with tumour thrombi have a higher stage and grade (level of evidence: 2b). Distant or lymph node metastases are twice as common (level of evidence: 3). This increased biological aggressiveness determines the clinical prognosis more than the presence or the cranial extension of intracaval thrombosis (level of evidence: 3) (9-22).

5.1.1.2 Recommendation

Surgical therapy is the only curative therapeutic approach for the treatment of RCC. In some selected cases with lymph node disease limited to the retroperitoneal space, extended lymphadenectomy might improve a patient's clinical prognosis. In general, extended lymphadenectomy cannot be considered to be the therapeutic standard. Adrenalectomy together with nephrectomy, except in the case of large upper pole tumours where direct invasion of the adrenal gland is likely, can be spared in the majority of patients (grade B recommendation). Embolization as a palliative approach can be beneficial in patients unfit for surgery with massive haematuria or profound local pain (grade C recommendation).

5.1.2 Nephron-sparing surgery

Standard indications for nephron-sparing surgery are divided into the following categories:

- absolute (anatomical or functional solitary kidney)
- relative (functioning opposite kidney that is affected by a condition that might impair renal function in future)
- elective (localized unilateral RCC with a healthy contralateral kidney).

Relative indications also include patients with hereditary forms of RCC, who are at high risk of developing a tumour in the contralateral kidney in the future.

5.1.2.1 Conclusion

Nephron-sparing surgery for RCC, when performed in patients with a solitary tumour less than < 4 cm maximum diameter, provides recurrence-free and long-term survival rates similar to those observed after a radical surgical procedure (level of evidence: 2b) (23-25).

After nephron-sparing surgery for absolute indications compared with elective indications, both the complication rate and the risk of developing locally recurrent disease appear to be elevated, probably due to the larger tumour size (level of evidence: 3) (26,27). There is some evidence that patients subjected to radical

nephrectomy compared with nephron-sparing surgery for RCC have an increased risk of impaired renal function, resulting in chronic renal insufficiency and proteinuria (level of evidence: 3) (28-30). In a few series, even patients with a tumour diameter up to 7 cm have been subjected to nephron-sparing surgery, delivering oncological results equivalent to those observed after a radical approach. If the tumour is completely resected, the thickness of the surgical margin does not impact on the likelihood for local recurrence (level of evidence: 3).

5.1.2.2 Recommendation

Nephron-sparing surgery is an established curative approach for the treatment of patients with RCC. Nephron-sparing surgery for the treatment of tumours more than 4-7 cm maximum diameter can be performed in centres with expertise in appropriate cases. A minimal tumour-free surgical margin following partial resection of kidney cancer appears appropriate to avoid the increased risk of local recurrence. If tumours of larger size are treated with nephron-sparing surgery, the follow-up should be intensified due to an increased risk of intrarenal recurrences (grade B recommendation).

5.1.3 Laparoscopic nephrectomy

Since its introduction, laparoscopic nephrectomy for RCC has become an established surgical procedure worldwide. Whether done retro- or trans-peritoneally, the laparoscopic approach has to duplicate established open surgical oncological principles, i.e. early control of the renal vessels before tumour manipulation, wide specimen mobilization external to Gerota's fascia, avoidance of specimen traumatization or rupture, and intact specimen extraction.

In the hands of experienced laparoscopic urological surgeons, and with adherence to the above-mentioned principles of open radical nephrectomy, laparoscopic radical nephrectomy may now be considered a standard of care for patients with T1-2 RCCs. Intermediate outcome data indicate equivalent cancer-free survival rates when compared with open radical nephrectomy.

5.1.3.1 Conclusion

Laparoscopy for radical nephrectomy has a lower morbidity when compared with open surgery (level of evidence: 3). Tumour control rates appear equivalent for T1-2 and possible T3a tumours in experienced hands (level of evidence: 3).

5.1.3.2 Recommendation

Laparoscopic tumour nephrectomy should be performed in centres with laparoscopic expertise. Laparoscopic tumour nephrectomy can be expected to become a widely distributed treatment option and should be promoted in centres treating kidney tumours (grade B recommendation).

5.1.4 Partial laparoscopic nephrectomy

In experienced hands, laparoscopic partial nephrectomy might be an alternative to open nephron-sparing surgery for very selected patients (31-34). The optimal indication for laparoscopic nephron-sparing surgery is a relatively small and peripheral renal tumour. Although the oncological outcome following laparoscopic partial nephrectomy has been suggested to duplicate that of open techniques of nephron-sparing surgery (35,36), larger studies that would reveal reliable long-term equivalence are not available at present. Suggested disadvantages of the laparoscopic approach are the longer warm ischaemia time and increased intra-operative and post-operative complications when compared with open surgery (37-39).

5.1.4.1 Conclusion

Partial nephrectomy by laparoscopic surgery is technically feasible (level of evidence: 2b).

5.1.4.2 Recommendation

Open partial nephrectomy currently remains the standard of care. Laparoscopic partial nephrectomy should be limited to experienced centres (grade C recommendation).

5.2 Alternative treatment

Image-guided percutaneous and minimally invasive techniques, e.g. percutaneous radiofrequency (RF) ablation (40,41), cryoablation (42), microwave ablation, laser ablation and high-intensity focused ultrasound ablation (HIFU) have been suggested as alternatives to the surgical treatment of RCC (level of evidence: 2b) (43).

Potential advantages of these and other techniques might include reduced morbidity, outpatient therapy, and the ability to treat high-risk surgical candidates (level of evidence: 2b).

Indications for minimally invasive techniques including RF ablation include small, incidentally found, renal cortical lesions in elderly patients, patients with genetic predisposition to multiple tumours, or patients

with a solitary kidney, or bilateral tumours (level of evidence: 2b).

Contraindications to the above-mentioned procedures include a poor life expectancy of < 1 year, multiple metastases, or difficulty for successful treatment due to size or location of tumour. In general, tumours > 5 cm or tumours in the hilum, the proximal ureter or central collecting system are not typically recommended for RF ablation (44). Absolute contraindications include irreversible coagulopathies or severe medical instability, such as sepsis.

Although, even in high-risk patients, the reported complication rates are low, greater multicentre experience is required to define the oncological success and complications after use of these procedures as an alternative to open or laparoscopic surgery.

5.2.1 Conclusion

The formerly mentioned, minimally invasive approaches currently have the status of experimental treatment options for kidney cancer. Their efficacy should be further evaluated within clinical trials. Their disadvantage is a lack of adequate histopathological evaluation. However, their advantage is decreased invasiveness enabling treatment of patients with reduced health condition, who are otherwise not fit for conventional surgery (level of evidence: 3).

5.2.2 Recommendation

Currently, patients not suitable for open or laparoscopic surgery due to poor performance status with smaller peripheral tumours should be considered for the above-mentioned techniques for RCC treatment (grade B recommendation).

5.3 Adjuvant therapy

Current evidence that adjuvant tumour vaccination might improve the duration of the progression-free survival of selected subgroups of patients undergoing nephrectomy for T3 renal carcinomas needs further confirmation regarding the impact on overall survival (level of evidence: 1b) (45-49). Prognostic algorithms might identify patients likely to derive the largest clinical benefit from adjuvant vaccination therapy.

5.3.1 Conclusion

Adjuvant therapy with cytokines does not improve survival after nephrectomy (level of evidence: 1b).

5.3.2 Recommendation

Outside controlled clinical trials, there is no indication for adjuvant therapy following surgery (grade A recommendation).

5.4 Surgical treatment of metastatic RCC (tumour nephrectomy)

Tumour nephrectomy is curative only if surgery can excise all tumour deposits. For the majority of patients with metastatic disease, tumour nephrectomy is palliative and other systemic treatments are necessary. In a meta-analysis of two randomized studies, comparing nephrectomy combined with immunotherapy versus immunotherapy only, an increased long-term survival was found in patients subjected to tumour nephrectomy (50). Nephrectomy in patients with metastatic disease is indicated for patients who are both suitable for surgery and have good performance status (51).

5.4.1 Conclusion

Tumour nephrectomy in combination with interferon-alpha (IFN-alpha) improves the survival of patients with metastatic RCC (mRCC) and good performance status (level of evidence: 1b).

5.4.2 Recommendation

Tumour nephrectomy is recommended for metastatic RCC patients with good performance status when combined with IFN-alpha (grade A recommendation).

5.5 Resection of metastases

Complete removal of metastatic lesions contributes to an improvement of clinical prognosis. Immunotherapy, where there has been complete resection of metastatic lesions or isolated local recurrences, does not contribute to an improvement in clinical prognosis (level of evidence: 2b) (51-55).

5.5.1 Conclusion

There is a definite role for metastasectomy in patients with RCC in order to improve the clinical prognosis (level of evidence: 3).

5.5.2 Recommendation

In patients with synchronous metastatic spread, metastasectomy should be performed where disease is resectable and the patient has a good performance status. The clinical prognosis is worse in patients who have surgery for metachranous metastases. Metastasectomy should be performed in patients with residual and resectable metastatic lesions previously responding to immunotherapy and/or a limited (solitary lesion) number of metachranous metastases in order to improve the patient's prognosis (grade B recommendation).

5.6 Radiotherapy for metastases in RCC

Radiotherapy can be used for selected symptomatic patients with non-resectable brain or osseous lesions who do not respond to other conservative treatment approaches (56,57).

5.6.1 Conclusion

Radiotherapy of metastases from renal cell cancer can induce a significant relief from symptoms with pain reduction, e.g. a single bony deposit (level of evidence: 2b).

5.6.2 Recommendation

In individual cases, radiotherapy for the treatment of brain metastases (whole brain irradiation or stereotactic approach) and osseous lesions can induce a relief from symptoms due to mRCC (grade B recommendation) (58,59).

5.7 REFERENCES

1. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. *J Urol* 1969;101(3):297-301.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=5765875&query_hl=129&itool=pubmed_docsum
2. Bakal CW, Cynamon J, Lakritz PS, Sprayregen S. Value of preoperative renal artery embolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. *J Vasc Interv Radiol* 1993;4(6):727-731.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8280991&query_hl=133&itool=pubmed_docsum
3. Hemingway AP, Allison DJ. Complications of embolization: analysis of 410 procedures. *Radiology* 1988;166(3):669-672.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3340761&query_hl=136&itool=pubmed_docsum
4. Hom D, Eiley D, Lumerman JH, Siegel DN, Goldfischer ER, Smith AD. Complete renal embolization as an alternative to nephrectomy. *J Urol* 1999;161(1):24-27.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10037359&query_hl=138&itool=pubmed_docsum
5. Lanigan D, Jurriaans E, Hammonds JC, Wells IP, Choa RG. The current status of embolization in renal cell carcinoma - a survey of local and national practice. *Clin Radiol* 1992;46(3):176-178.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1395422&query_hl=140&itool=pubmed_docsum
6. Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. *BJU Int* 2003;92(3):240-244.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12887475&query_hl=142&itool=pubmed_docsum
7. Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. *BJU Int* 2001;87(4):312-315.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11251521&query_hl=144&itool=pubmed_docsum
8. Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. *Am J Clin Oncol* 2000; 23(1):6-12.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10683065&query_hl=146&itool=pubmed_docsum
9. O'Brien WM, Lynch JH. Adrenal metastases by renal cell carcinoma. Incidence at nephrectomy. *Urology* 1987;29(6):605-607.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3576885&query_hl=148&itool=pubmed_docsum

10. Angervall L, Wahlqvist L. Follow-up and prognosis of renal carcinoma in a series operated by perifascial nephrectomy combined with adrenalectomy and retroperitoneal lymphadenectomy. *Eur Urol* 1978;4(1):13-17.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=627219&query_hl=150&itool=pubmed_docsum
11. Kozak W, Holtl W, Pummer K, Maier U, Jeschke K, Bucher A. Adrenalectomy-still a must in radical renal surgery? *Br J Urol* 1996;77(1):27-31.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8653312&query_hl=152&itool=pubmed_docsum
12. Kuczyk M, Munch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, Kollmannsberger C, Kondo M, Jonas U. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. *BJU Int* 2002;89(6):517-522.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11942955&query_hl=154&itool=pubmed_docsum
13. Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. *Eur Urol* 2005;48(2):252-257.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15936136&query_hl=156&itool=pubmed_docsum
14. Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. *Urology* 1997;49(1):28-31.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9000180&query_hl=158&itool=pubmed_docsum
15. Li GR, Soulie M, Escourrou G, Plante P, Pontonnier F. Micrometastatic adrenal invasion by renal carcinoma in patients undergoing nephrectomy. *Br J Urol* 1996;78(6):826-828.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9014703&query_hl=160&itool=pubmed_docsum
16. Leibovitch I, Raviv G, Mor Y, Nativ O, Goldwasser B. Reconsidering the necessity of ipsilateral adrenalectomy during radical nephrectomy for renal cell carcinoma. *Urology* 1995;46(3):316-20.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7660505&query_hl=162&itool=pubmed_docsum
17. von Knobloch R, Seseke F, Riedmiller H, Grone HJ, Walthers EM, Kalble T. Radical nephrectomy for renal cell carcinoma: is adrenalectomy necessary? *Eur Urol* 1999;36(4):303-308.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10473989&query_hl=164&itool=pubmed_docsum
18. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrin AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. *J Urol* 2003;169(3):909-916.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12576811&query_hl=166&itool=pubmed_docsum
19. Bissada NK, Yakout HH, Babanouri A, Elsalamony T, Fahmy W, Gunham M, Hull GW, Chaudhary UB. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. *Urology* 2003;61(1):89-92.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12559273&query_hl=168&itool=pubmed_docsum
20. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. *Eur Urol* 1997; 31(1):40-48.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9032533&query_hl=170&itool=pubmed_docsum
21. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. *J Urol* 1996;155(2):448-450.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8558632&query_hl=172&itool=pubmed_docsum
22. Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. *Ann Surg* 1989;210(3):387-392; discussion 392-394.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2774709&query_hl=174&itool=pubmed_docsum

23. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. *J Urol* 2000;163(3):730-736.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10687966&query_hl=1&itool=pubmed_docsum
24. Uzzo RG, Novick AC. Nephron-sparing surgery for renal tumors: indications, techniques and outcomes. *J Urol* 2001;166(1):6-18.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11435813&query_hl=3&itool=pubmed_docsum
25. Delakas D, Karyotis I, Daskalopoulos G, Terhorst B, Lymberopoulos S, Cranidis A. Nephron-sparing surgery for localized renal cell carcinoma with a normal contralateral kidney: a European three-center experience. *Urology* 2002;60(6):998-1002.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12475657&query_hl=5&itool=pubmed_docsum
26. Kural AR, Demirkesen O, Onal B, Obek C, Tunc B, Onder AU, Yalcin V, Solok V. Outcome of nephron-sparing surgery: elective versus imperative indications. *Urol Int* 2003;71(2):190-196.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12890959&query_hl=7&itool=pubmed_docsum
27. Hafez KS, Fergany AF, Novick AC. Nephron-sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. *J Urol* 1999;162(6):1930-1933.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10569540&query_hl=9&itool=pubmed_docsum
28. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. *Urology* 2002;60(6):1003-1009.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12475658&query_hl=11&itool=pubmed_docsum
29. Lundstam S, Jonsson O, Lyrdal D, Peeker R, Pettersson S. Nephron-sparing surgery for renal cell carcinoma-long-term results. *Scand J Urol Nephrol* 2003;37(4):299-304.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12944187&query_hl=13&itool=pubmed_docsum
30. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. *Mayo Clin Proc* 2000;75(12):1236-1242.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11126830&query_hl=15&itool=pubmed_docsum
31. Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney AM, Kaouk JH, Gill IS. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. *J Urol* 2005;173(1):38-41.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15592021&query_hl=17&itool=pubmed_docsum
32. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? *Curr Opin Urol* 2005;15(2):75-78.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15725928&query_hl=19&itool=pubmed_docsum
33. Link RE, Bhayani SB, Allaf ME, Varkarakis I, Inagaki T, Rogers C, Su LM, Jarrett TW, Kavoussi LR. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. *J Urol* 2005;173(5):1690-1694.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15821559&query_hl=21&itool=pubmed_docsum
34. Novick AC. Laparoscopic and partial nephrectomy. *Clin Cancer Res* 2004;10(18 Pt 2):6322S-6327S.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15448025&query_hl=23&itool=pubmed_docsum
35. Porpiglia F, Fiori C, Terrone C, Bollito E, Fontana D, Scarpa RM. Assessment of surgical margins in renal cell carcinoma after nephron sparing: a comparative study: laparoscopy vs open surgery. *J Urol* 2005;173(4):1098-1101.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15758709&query_hl=25&itool=pubmed_docsum

36. Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm or less renal tumor with a normal contralateral kidney. *J Urol* 2002; 168(4 Pt 1):1356-1359; discussion 1359-1360.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12352392&query_hl=27&itool=pubmed_docsum
37. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T. Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. *J Urol* 2003;169(6):2072-2075.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12771722&query_hl=29&itool=pubmed_docsum
38. Makhoul B, De La Taille A, Vordos D, Salomon L, Sebe P, Audet JF, Ruiz L, Hoznek A, Antiphon P, Cicco A, Yiou R, Chopin D, Abbou CC. Laparoscopic radical nephrectomy for T1 renal cancer: the gold standard? A comparison of laparoscopic vs open nephrectomy. *BJU Int* 2004;93(1):67-70.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14678371&query_hl=31&itool=pubmed_docsum
39. Wille AH, Roigas J, Deger S, Tullmann M, Turk I, Loening SA. Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. *Eur Urol* 2004;45(4):483-488; discussion 488-489.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15041113&query_hl=33&itool=pubmed_docsum
40. Lui KW, Gervais DA, Mueller PR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. *Chang Gung Med J* 2004;27(8):618-623.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15553610&query_hl=35&itool=pubmed_docsum
41. Lewin JS, Nour SG, Connell CF, Sulman A, Duerk JL, Resnick MI, Haaga JR. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. *Radiology* 2004;232(3):835-845.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15333798&query_hl=37&itool=pubmed_docsum
42. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC. Renal cryoablation: outcome at 3 years. *J Urol* 2005;173(6):1903-1907.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15879772&query_hl=39&itool=pubmed_docsum
43. Lin CH, Moinzadeh A, Ramani AP, Gill IS. Histopathologic confirmation of complete cancer-cell kill in excised specimens after renal cryotherapy. *Urology* 2004;64(3):590.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15351611&query_hl=41&itool=pubmed_docsum
44. Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma. *Clin Cancer Res* 2004;10(18 Pt 2):6328S-6334S.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15448026&query_hl=43&itool=pubmed_docsum
45. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarossa M, Sacco C, Talamini R. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. *Cancer* 1996; 77(12):2560-2566.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8640706&query_hl=45&itool=pubmed_docsum
46. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Beldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol* 1999;17(8):2521-2529.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10561318&query_hl=47&itool=pubmed_docsum
47. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. *J Clin Oncol* 2003;21(16):3133-3140.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12810695&query_hl=49&itool=pubmed_docsum

48. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *Br J Cancer* 2005;92(5):843-846.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15756254&query_hl=51&itool=pubmed_docsum
49. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. *Lancet* 2004;363(9409):594-599.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14987883&query_hl=53&itool=pubmed_docsum
50. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 2004;171(3):1071-1076.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14767273&query_hl=55&itool=pubmed_docsum
51. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. *Scand J Urol Nephrol* 2000;34(4):246-251.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11095082&query_hl=16&itool=pubmed_docsum
52. Pongracz N, Zimmerman R, Kotz R. Orthopaedic management of bony metastases of renal cancer. *Semin Surg Oncol* 1988;4(2):139-142.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3393777&query_hl=59&itool=pubmed_docsum
53. Tongaonkar HB, Kulkarni JN, Kamat MR. Solitary metastases from renal cell carcinoma: a review. *J Surg Oncol* 1992;49(1):45-48.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1548881&query_hl=61&itool=pubmed_docsum
54. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. *Eur Urol* 1999;35(3):197-203.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10072620&query_hl=63&itool=pubmed_docsum
55. Jackson RJ, Loh SC, Gokaslan ZL. Metastatic renal cell carcinoma of the spine: surgical treatment and results. *J Neurosurg* 2001;94(1 Suppl):18-24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11147860&query_hl=65&itool=pubmed_docsum
56. Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. *Eur Urol* 1982;8(6):340-342.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=6183119&query_hl=67&itool=pubmed_docsum
57. Gez E, Libes M, Bar-Deroma R, Rubinov R, Stein M, Kuten A. Postoperative irradiation in localized renal cell carcinoma: the Rambam Medical Center experience. *Tumori* 2002;88(6):500-502.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12597146&query_hl=69&itool=pubmed_docsum
58. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryj J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 2004;363(9422):1665-1672.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15158627&query_hl=71&itool=pubmed_docsum
59. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. *J Clin Oncol* 1998;16(6):2261-2266.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9626229&query_hl=73&itool=pubmed_docsum

6. SYSTEMIC THERAPY FOR METASTATIC RCC

6.1 Chemotherapy

Since RCCs develop from the proximal tubules, they have high levels of expression of the multiple-drug resistance protein P-glycoprotein and are therefore resistant to most chemotherapies. Chemotherapy seems to be effective only if 5-fluorouracil (5FU) is combined with immunotherapeutic agents (1).

6.1.1 Conclusion

Only 5FU in combination with immunotherapy seems to be effective in patients with mRCC (level of evidence: 3).

6.1.2 Recommendation

Chemotherapy as monotherapy should not be considered effective in patients with mRCC (grade B recommendation).

6.2 Immunotherapy

6.2.1 Interferon-alpha

In randomized studies, IFN-alpha has proven superiority for survival over hormonal therapy in patients with mRCC (2). The studies were done using the regimen of IFN-alpha, 10MU, three times per week for 12 weeks. The patients who benefited had a good WHO status (0-1) and were treated for at least 12 weeks and up to 1 year. However, IFN-alpha provided a response rate of 6-15%, together with a 25% decrease in the risk for tumour progression, and a modest survival benefit of 3-5 months when compared with placebo-equivalent (3,4).

6.2.1.1 Conclusion

Immunotherapy with INF-alpha is beneficial for mRCC patients with a good performance status, a progression-free survival following initial diagnosis of more than 1 year, and preferably lung metastasis as the sole metastatic site (level of evidence: 1b).

6.2.2 Interleukin-2

Interleukin-2 (IL-2) has been used in mRCC since 1985. Several studies have shown responses ranging from 7-27% (5-7). The optimal IL-2 regimen is not clear, but long-term (> 10 years) complete responders have been achieved with high-dose bolus IL-2 (8). The toxicity of IL-2 is substantially higher than that of IFN-alpha. It seems that only clear cell type RCC responds to immunotherapy. Interleukin-2 has not been validated in controlled randomized studies compared with best supportive care (4).

6.2.2.1 Conclusion

Interleukin-2 has more side-effects than INF-alpha. High-dose IL-2 gives durable complete responders in a limited number of patients. To date, no superiority has been seen for treatment with either INF-alpha or IL-2 in mRCC patients (level of evidence: 1b).

6.2.3 Combinations of cytokines

Several randomized studies have been performed to investigate the efficacy of combinations of cytokines. Combination therapy moderately improved the response rate and progression-free survival. However, patient survival was not better than survival achieved with monotherapy regimens (9). Furthermore, it did not reveal an impact on patients' overall survival compared to placebo-equivalent therapy, at least in intermediate-risk patients (10). No other combinations with cis-retinoic acid or 5FU have shown a clinical significant benefit, although some survival advantage has been seen (11,12).

6.2.3.1 Conclusion

To date, combination therapy has not shown any clinical benefit in mRCC patients (level of evidence: 1b).

6.2.4 Recommendations

Interferon-alpha can be considered as a control arm for studies investigating the efficacy of new drugs in mRCC patients (grade A recommendation). Only selected patients with mRCC, revealing a good risk profile, and clear cell subtype histology derive clinical benefit from immunotherapy with IL-2 or IFN-alpha (grade B recommendation). Combination of cytokines, with or without additional chemotherapy, does not improve overall survival compared with monotherapy (grade A recommendation).

6.3 Angiogenesis inhibitor drugs

Recent advances in the understanding of the molecular biology have led to the development of several novel agents for the treatment of mRCC.

In sporadic clear cell RCC, HIF accumulation due to VHL inactivation, results in overexpression of VEGF and PDGF (platelet-derived growth factor) both promoting neoangiogenesis (13-15). This process substantially contributes to the development and progression of RCC. Recently, two antiangiogenic drugs have been approved both in the USA and in Europe for the treatment of mRCC: sorafenib (Nexavar[®]) and sunitinib (Sutent[®]). The position of these novel agents with regard to primary or secondary treatments of mRCC is still under investigation, as well as combinations of these new agents with each other or with cytokines.

6.3.1 Sorafenib

Sorafenib is an oral multikinase inhibitor with activity against Raf-1 serine/threonine kinase, B-Raf, VEGFR-2, PDGFR, FLT-3 and c-KIT. A phase III trial comparing sorafenib and placebo after failure of a prior systemic immunotherapy reported a 3-month improvement in progression-free survival in favour of therapy with sorafenib (16). Overall survival data are currently not available.

6.3.2 Sunitinib

Sunitinib is an oxindol tyrosine kinase (TK) inhibitor. It is a small molecule with antitumour and antiangiogenic activity that selectively multitargets inhibition of PDGFR, VEGFR, KIT and FLT-3. Two multicentre phase II trials with sunitinib as second-line monotherapy in patients with mRCC demonstrated a 34-40% partial response rate and 27-29% of patients who had stable disease \geq 3 months (17). A phase III trial evaluating sunitinib as first-line monotherapy compared to IFN-alpha has been recently reported. The median progression-free survival was longer for patients treated with sunitinib (11 months) than for those treated with IFN-alpha (5 months), $p < 0.000001$, suggesting treatment with IFN-alpha for low- and intermediate-risk patients with mRCC is inferior as first-line therapy compared with sunitinib (18). Overall survival data are awaited.

6.3.3 New drugs

Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) (19). A phase III trial comparing temsirolimus, INF-alpha and their combination in patients with advanced RCC as first-line therapy has recently been reported. Temsirolimus monotherapy was shown to increase overall survival in poor-risk patients with mRCC compared to treatment with IFN-alpha monotherapy or IFN-alpha combined with temsirolimus (20). A number of other new drugs targeting angiogenesis are under investigation.

6.3.4 Conclusion

Tyrosine kinase inhibitors increase progression-free survival as both first- and second-line treatment of mRCC (level of evidence: 1b). Sorafenib has proven efficacy as second-line treatment after failure of cytokine therapy (level of evidence: 1b). Sunitinib is more effective than interferon in cytokine-naïve, good- and intermediate-risk tumours (level of evidence: 1b). Temsirolimus monotherapy in poor-risk patients is more effective than IFN-alpha or temsirolimus plus interferon (level of evidence: 1b).

The role of the new drugs is still under debate. Combination studies are currently ongoing. To date, no data are available indicating these new agents have a curative effect. These agents appear to promise to stabilise mRCC for a prolonged period of time. Preferably within combination regimens, this has to be balanced against the toxicity profile and the maintenance of quality of life (level of evidence: 4).

6.3.5 Recommendations

- Tyrosine kinase inhibitors should be considered as first- or second-line treatment for mRCC patients (grade A recommendation).
- Sorafenib is advised as a second-line treatment for mRCC (grade A recommendation).
- Sunitinib is advised as first-line therapy in good- and intermediate-risk patients (grade A recommendation).
- Temsirolimus should be considered as first-line treatment in poor-risk patients (grade A recommendation).

6.4 REFERENCES

1. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. *J Urol* 2003;170(4 Pt 1):1141-1145.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14501711&query_hl=9&itool=pubmed_docsum
2. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. *Medical Research Council Renal Cancer Collaborators. Lancet* 1999;353(9146):14-17.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10023944&query_hl=11&itool=pubmed_docsum
3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002;20(1):289-296.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11773181&query_hl=44&itool=pubmed_docsum
4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. *Cochrane Database Syst Rev* 2005;(1):CD001425.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15674877&dopt=Abstract
5. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang A E, Schwartzentruber DJ, Aebbersold P, Leitman S, Linehan WM, Seipp CA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 1993;21(85):622-632.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8468720&query_hl=13&itool=pubmed_docsum
6. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1995;13(3):688-696.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7884429&query_hl=15&itool=pubmed_docsum
7. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith, JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2005;23(1):133-141.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15625368&query_hl=17&itool=pubmed_docsum
8. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol* 2003; 21(16):3127-3132.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12915604&query_hl=19&itool=pubmed_docsum
9. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. *Groupe Français d'Immunothérapie. N Engl J Med* 1998;338(18):1272-1278.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9562581&query_hl=22&itool=pubmed_docsum
10. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Tubiana-Mathieu N, Escudier B., and the French Immunotherapy Intergroup. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. 2005 ASCO Annual Meeting Proceedings. *J Clin Oncol* 2005;23(16S):4511.
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31254

11. Aass N, De Mulder PH, Mickisch GH, Mulders P, Van Oostrom AT, Van Poppel H, Fossa SD, De Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) *J Clin Oncol* 2005;23(18):4172-4178.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15961764&query_hl=24&itool=pubmed_docsum
12. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstern H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *J Clin Oncol* 2004;22(7):1188-1194. Epub 2004 Feb 23.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14981107&query_hl=28&itool=pubmed_DocSum
13. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. *Clin Cancer Res* 2006;12(24):7215-7220.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17189392&query_hl=19&itool=pubmed_docsum
14. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349(5):427-434.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12890841&query_hl=28&itool=pubmed_docsum
15. Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. *Eur Urol* 2006;49(4):633-643. Epub 2006 Feb 2.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16481093&query_hl=17&itool=pubmed_docsum
16. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreaux C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007;356(2):125-134.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17215530&query_hl=14&itool=pubmed_docsum
17. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2006;24(1):16-24. Epub 2005 Dec 5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16330672
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007;356(2):115-124.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17215529&query_hl=6&itool=pubmed_docsum
19. Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. *Crit Rev Oncol Hematol* 2006; 60(3):216-226. Epub 2006 Jul 24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16860997&query_hl=26&itool=pubmed_docsum
20. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). 2006 ASCO Annual Meeting Proceedings. *J Clin Oncol* 2006; 24(18S):LBA4.
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=30421

7. SURVEILLANCE FOLLOWING RADICAL SURGERY FOR RCC

7.1 Introduction

Surveillance after radical surgery allows the urologist to monitor or identify:

- post-operative complications
- renal function
- local recurrence
- recurrence in the contralateral kidney
- development of metastases.

The method and timing of investigation has been the subject of many publications. There is no consensus on surveillance after radical surgery of the kidney.

Post-operative complications and renal function are readily assessed by history, physical examination and measurement of serum creatinine. Repeated long-term monitoring of creatinine levels is indicated if there is impaired renal function before surgery or a post-operative significant increase in the serum creatinine level (1).

Local recurrence is rare (1.8%), but early diagnosis is useful since the most effective treatment is cytoreductive surgery (2,3). Recurrence in the contralateral kidney is also rare (1.2%) and is related to positive margins, multifocality and grade (4).

The reason for surveillance is to identify metastases early. This is because more extended tumour growth can reduce the possibility of surgical resection, which is considered the standard therapy in cases of resectable and preferably solitary metastatic lesions. In addition, within clinical trials, an early diagnosis of tumour recurrence might enhance the efficacy of a systemic treatment if the tumour burden is low.

7.2 Which investigations for which patients, and when?

Repeated intensive radiological surveillance for all patients is unnecessary because, for example, the outcome after surgery for small, well-differentiated tumours is almost always excellent. It is therefore reasonable to modify follow-up, taking into account the risk of developing recurrence or metastases. No randomized evidence exists, but there are large studies with long follow-up from which some conclusions can be drawn (level of evidence: 4).

Factors influencing prognosis can be classified into: anatomical, histological, clinical and molecular (5,6). Anatomical factors include: tumour size, stage, venous invasion, adrenal involvement and lymph node status. Histological factors include: grade, presence of sarcoma, necrosis and collecting system invasion. Clinical factors include: patient performance status, anaemia, platelet count and cachexia.

There are also numerous molecular markers that are being investigated with respect to future treatments. These markers include immunotherapy, vaccine, gene and angiogenesis techniques, but as yet none of these are in widespread use.

7.3 Imaging modalities

Where the likelihood of relapse is low, chest X-ray and US are appropriate. Where the risk is intermediate or high, CT of chest and abdomen is the investigation of choice, though the significant morbidity of radiation dose with repeated CT scans should be taken into account (7).

Dependent on the availability of new effective treatments more strict follow-up schedules may be required. Another problematic issue is the optimal duration of the follow-up. One may argue the follow-up by imaging is not cost effective after 5 years (8). Late metastases are more frequently solitary and these justify more aggressive therapy with curative intent. Also patients with tumors that develop in the contralateral kidney (2-3%) can be treated with nephron-sparing surgery when detected with a small size. Furthermore, for tumors <4cm there seems to be no obvious difference in recurrence in the follow-up after partial or radical nephrectomy (9).

Using many of these variables, several groups have designed scoring systems and algorithms to stratify patients into low-, intermediate- and high-risk groups for developing tumour recurrence or metastases. The frequency and type of investigation are different for each group (10-13). Examples of these scoring systems are shown in Tables 3 and 4.

Table 3: Scoring algorithm to predict metastases after nephrectomy in patients with clear cell renal cell carcinoma according to the Mayo Scoring System (13)

Feature	Score
<i>Primary tumor / T-stage</i>	
T1a	0
pT1b	2
pT2	3
pT3 - pT4	4
<i>Tumor size</i>	
<10cm	0
>10cm	1
<i>Regional Lymph Node status</i>	
pNx/pN0	0
pN1 - pN2	2
<i>Nuclear grade</i>	
Grade 1-2	0
Grade 3	1
Grade 4	3
<i>Tumor necrosis</i>	
No necrosis	0
Necrosis	1

Risk groups can be stratified by the scoring system, characterized into low-risk 0-2, intermediate risk 3-5 and high-risk >6 according to the Mayo Scoring System (13).

Table 4: Accumulated risk of metastases (%) after nephrectomy in patients with clear cell renal cell carcinoma as defined in risk groups according to the Mayo Scoring System (13)

Risk group	Year 1	Year 3	Year 5	Year 10
Low	0.5	2.1	2.9	7.5
Intermediate	9.6	20.2	26.2	35.7
High	42.3	62.9	68.8	76.4

The use of these scoring systems allows the urologist to be selective in the use of imaging and to appropriately target those patients most in need of intensive surveillance.

7.4 Conclusion

In cases where there is a very low risk for tumour recurrence or systemic tumour progression, CT scans can be omitted as routine follow-up examinations. In these patients, a CT scan is only justified in cases of possible tumour-associated symptoms. In the intermediate-risk group, an intensified follow-up that includes CT scans at regular time intervals should be performed according to a risk-stratified nomogram. In high-risk patients, the follow-up examinations should include routine CT scans (level of evidence: 4).

7.5 Recommendation

The intensity of the follow-up programme for an individual patient should be adapted according to the risk of tumour recurrence or systemic tumour progression, as determined by a risk nomogram developed for risk stratification (grade C recommendation).

7.6 REFERENCES

1. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. *Mayo Clinic Proc* 2000;75(12):1236-1242.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11126830&query_hl=77&itool=pubmed_docsum
2. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal fossa recurrence after nephrectomy. *J Urol* 2000;164(2):322-325.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10893575&query_hl=79&itool=pubmed_docsum
3. Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. *BJU Int* 2005;95(4):522-525.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15705072&query_hl=81&itool=pubmed_docsum
4. Bani-Hani AH, Leibovich BC, Lohse CM, Chevillie JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. *J Urol* 2005;173(2):391-394.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15643178&query_hl=84&itool=pubmed_docsum
5. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *J Urol* 2005;173(6):1853-1862.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15879764&query_hl=87&itool=pubmed_docsum
6. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histological subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol* 2005;23(12):2763-2771.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15837991&query_hl=89&itool=pubmed_docsum
7. Ionising Radiation (Medical Exposures) Regulations 2000. National Radiation Protection Board 2000
www.hpa.org.uk
http://www.hpa.org.uk/radiation/understand/radiation_topics/medical/diagnostic_radiology/national_reference_doses.htm
8. Montie J. Follow-up after partial or total nephrectomy for renal cell carcinoma. *Urol Clin North Am* 1994;21(4):589-592.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7974891&query_hl=40&itool=pubmed_docsum
9. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. *J of Urol* 2004;171(6 Pt 1):2181-2185.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15126781&query_hl=42&itool=pubmed_docsum
10. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. *BJU Int* 1999;84(4): 405-411.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10468753&query_hl=91&itool=pubmed_docsum
11. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001;166(1):63-67.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11435824&query_hl=93&itool=pubmed_docsum
12. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognosticated nomogram and risk group stratification system. *J Urol* 2005;174(2):466-472.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16006866&query_hl=96&itool=pubmed_docsum
13. Leibovich BC, Blute ML, Chevillie JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer* 2003;97(7):1663-1671.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12655523&query_hl=98&itool=pubmed_docsum

8. ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations

5FU	5-fluorouracil
CT	computerized tomography
HIF	hypoxia inducible factor
HIFU	high-intensity focused ultrasound
IFN-alpha	interferon-alpha
IL-2	interleukin-2
mRCC	metastatic renal cell carcinoma
MRI	magnetic resonance imaging
mTOR	mammalian target of rapamycin
PDGF	platelet-derived growth factor
PDGFR	platelet-derived growth factor receptor
RCC	renal cell carcinoma
RF	radiofrequency
TNM	Tumour Node Metastasis
US	abdominal ultrasound
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
VHL	von Hippel-Lindau
WHO	World Health Organization

Conflict of interest

All members of the Renal Cell Carcinoma guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved.